

### Agenda

<b>Title of Meeting</b>	Prescribing and Medicines Management
<b>Date</b>	17 <sup>th</sup> January 2018
<b>Time</b>	9.15am – 1pm
<b>Venue</b>	Meeting Room 2, Wynford House, Yeovil

Please notify Zoe Talbot-White if you are unable to attend at: [REDACTED]

Agenda Number	Item Description and Action	Item Presenter / Details of Enclosed Papers
<b>1</b>	Introductions	
<b>2</b>	Apologies for absence: James Nicholls, Gordon Jackson	
<b>3</b>	Declarations of interest	See last page of agenda
<b>4</b>	Minutes of the meeting on 15 <sup>th</sup> November 2017 • Review of action points	Attachment 4
	<b>PART 1 – Items for discussion or decision</b>	
<b>5</b>	<b>Matters Arising</b>	
5.1	De-prescribing antidepressants guidance.	Steve DuBois Attachment 5.1a,b
5.2	Over medication of patients with learning disabilities audit	Steve DuBois
5.3	Alfacalcidol Monitoring Guidance	Attachment 5.3
5.4	Prescribing requests for children's use in care settings, where these items can be purchased over the counter (OTC)	For discussion Rob Munro
5.5	DVT Treatment Pathway	Attachment 5.5
5.6	Draft single SCG for DMARDs (on SPF agenda)	Attachment 5.6
<b>6</b>	<b>Other Issues</b>	
6.1	Somerset CCG Out of Stock Guidance and Guidance for pharmacists on the repeal of Section 10(7) of the Medicines Act 1968	Attachment 6.1a & b
6.2	NHSE- Items which should not routinely be prescribed in primary care: Guidance for CCGs	Attachment 6.2
6.3	NHSE- Conditions for which over the counter items should not routinely be prescribed in primary care: A consultation on guidance for CCGs.	Attachment 6.3
6.4	Somerset CCG Self-care leaflet and poster	Attachment 6.4a, b & c
6.5	SPS- Suggestions for drug monitoring in adults in primary care	Attachment 6.5
6.6	RPC- National Early Warning Score	Attachment 6.6
6.7	2018-2019 Flu vaccine updated guidance	Attachment 6.7a & b Piers Jennings

6.8	Draft PGD: Supply of silver sulfadiazine 1% cream for impetigo by community pharmacists	Attachment 6.8
6.9	NCSO impact data (Nov & Dec estimate)	Attachment 6.9
6.10	Category M list January 18	Attachment 6.10
6.11	The use of unlicensed medicines in psychiatric practice	Attachment 6.11
6.12	Regional drug and therapeutics centre (Newcastle) Cost comparison charts August 2017	Attachment 6.12
<b>7</b>	<b>Scorecard indicator suggestions</b>	
7.1	Scorecard proposals	Attachment 7.1a,b
7.2	Scorecard indicator suggestion – Low value meds	Attachment 7.2
7.3	Hayfever medicine's data review	Attachment 7.3
<b>8</b>	<b>Formulary Applications</b>	
8.1	<a href="#">Trelegy Ellipta</a> <sup>®</sup> inhalation powder pre-dispensed (Fluticasone furoate 92mcg/ Umeclidinium 55mcg/ Vilanterol 22mcg) 1x 30 dose £44.50 (GlaxoSmithKline UK) Is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting $\beta$ 2-agonist.	<a href="#">See Link to SPC</a>
8.2	Delmosart <sup>®</sup> (methylphenidate) Prolonged Release Tablets <a href="#">18mg x 30 £15.59</a> ; <a href="#">27mg x 30 £18.41</a> ; <a href="#">36mg x 30 £21.23</a> ; <a href="#">54mg x 30 £36.81</a> (Accord) Is indicated as part of a comprehensive treatment programme for ADHD in children aged 6 years of age and over when remedial measures alone prove insufficient. Treatment must be under the supervision of a specialist in childhood behavioural disorders.	See Links to SPCs Bioequivalent data Attachment 8.2 (not shared)
8.3	Desitrend <sup>®</sup> (Levetiracetam) granules in sachets minitablets <a href="#">60x 250mg £22.41</a> ; <a href="#">60x 500mg £39.46</a> ; <a href="#">60x 1000mg £76.27</a> ; (Desitin Pharma Ltd) Is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.  Is indicated as adjunctive therapy: • in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy. • in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. • in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.	See Links to SPCs Attachment 8.3
<b>9</b>	<b>Reports from other meetings</b>	
	<b>Feedback</b>	
9.1	Commissioning Locality Feedback	
9.2	COG Feedback	
	<b>Summary</b>	

9.3	Somerset Partnership Mental Health D&TC – Last Meeting 05/12/17- Minutes received	
9.4	YDH D&TC – Last meeting 22/11/17 cancelled – no new minutes	
9.5	T&ST D&TC – Last meeting 10/11/17- Minutes not received	
9.6	BNSSG Joint Formulary Group – Last meetings 05/09/17, 17/10/17, 28/11/17 – Minutes received	
9.7	BNSSG D&TC — Last meetings 20/09/17, 29/11/17 – Minutes received	
9.8	RUH Bath D&TC – Last meetings 12/10/17, (9/11/17,-cancelled) 14/12/17 – October Minutes received	
9.9	Weston D&TC – Last meeting 9/11/17 – Minutes received	
9.10	T&S Antimicrobial Prescribing Group – Last meeting 8/11/17 – Minutes received	
9.11	Somerset Antimicrobial Stewardship Group – Next meeting not scheduled	
9.12	LPC Report	
9.13	Somerset Medication Safety Network – Next meeting not scheduled	
	<b>Part 2 – Items for Information or Noting</b>	
<b>10</b>	<b>Current Performance</b>	
10.1	Prescribing Update	To be tabled
10.2	October Scorecard commissioning locality trend	Attachment 10.2
10.3	October Safety spreadsheet	Attachment 10.3
10.4	Potential Generic Savings July-Sept 17	Attachment 10.4
10.5	Medicines Optimisation Dashboard	To be tabled
10.6	Toolkit Graphs	Attachment 10.6a & b
<b>11</b>	<b>Rebate Schemes</b>	
	None	
<b>12</b>	<b>NICE Guidance <a href="#">December 17</a> and <a href="#">January 18</a></b>	See links for guidance by month
<b>13</b>	<b>NICE Technology Appraisals</b>	
13.1	<a href="#">TA494 Naltrexone–bupropion for managing overweight and obesity</a>	See Link
<b>14</b>	<b>NICE Clinical Guidance</b>	
14.1	<a href="#">CG128 Autism spectrum disorder in under 19s: recognition, referral and diagnosis</a> –Updated December 2017, NICE reviewed the evidence and added ADHD as a factor associated with an increased prevalence of autism and changed references from DSM-4 to DSM-5.	See Link
14.2	<a href="#">NG80 Asthma: diagnosis, monitoring and chronic asthma management</a> -New	See Link, <a href="#">BMJ key differences</a>

14.3	<a href="#">QS124 Suspected cancer</a> –Update, definition update for testing for blood in faeces.	See Link
<b>15</b>	<b>Safety Items, NPSA Alerts and Signals</b>	
15.1	MHRA Drug Safety Update <a href="#">November</a> , <a href="#">December</a> & <a href="#">January</a>	See Links
15.2	Patient Safety alert: <a href="#">Confirming removal or flushing of lines and cannulae after procedures</a>	See Link
<b>16</b>	<b>BNF Changes</b>	
16.1	BNF Update <a href="#">November</a> and <a href="#">December</a>	See link
<b>17</b>	<b>Any other business</b>	
17.1	Palliative care pharmacies – For information	
17.2	GP practice prescribing budget allocation	
17.3	Change in smoking cessation services	
17.4	Possibility of change to SomPar dressings service	
	<b>Dates of Next Meetings:</b>	
	21 <sup>st</sup> February 2018	MR3 Wynford House
	14 <sup>h</sup> March 2018 (SPF following)	MR2 Wynford House
	18 <sup>h</sup> April 2018	MR2 Wynford House
	23 <sup>rd</sup> May 2018 (SPF following)	MR1 Wynford House
	20 <sup>h</sup> June 2018	MR2 Wynford House
	18 <sup>h</sup> July 2018 (SPF following)	MR2 Wynford House
	19 <sup>h</sup> September 2018 (SPF following)	MR2 Wynford House
	24 <sup>h</sup> October 2018	MR2 Wynford House
	21 <sup>st</sup> November 2018 (SPF following)	MR2 Wynford House

#### Distribution (as of September 2017)

Dr Toby Burne  
Dr Helen Cotton  
Dr David Davies  
Steve DuBois  
Dr Adrian Fulford  
Shaun Green

Liz Harewood  
Catherine Henley  
Gordon Jackson  
Dr Piers Jennings  
Michael Lennox  
Dr Catherine Lewis

Sam Morris  
Dr Robert Munro  
Dr James Nicholls  
Dr Geoff Sharp  
Zoe Talbot-White  
Dr Harry Yoxall

#### For Information

██████████  
██████████  
██████████  
Dr Ed Ford

██████████  
██████████  
Karen Taylor  
██████████

██████████  
██████████

# NHS Somerset CCG

## Prescribing and Medicines Management Group

### DECLARATION OF INTERESTS

Name	Position	Interests Declared
Dr Geoff Sharp	Chair	GP Partner, The Park Medical Partnership, PMS Practice Somerset CCG Governing Body GP The Park Medical Practice is a provider of medical services to Shepton Mallet Community Hospital (under contract to Somerset Partnership NHS Foundation Trust) Provides Out-of-Hours services for Somerset Doctors and Urgent Care (SDUC) Member of Somerset Primary Healthcare
Dr Toby Burne	CLICK Representative	GP Partner, prescribing and dispensary lead Summervale Medical Centre. Work at MPH as a GP in A&E. Member of Somerset Primary Healthcare
Dr Helen Cotton	South Somerset representative	GP, Hendford Lodge Medical Centre. Hendford Lodge has Oasis and Leg ulcer contract.
Dr David Davies	West Somerset Representative	GP Partner, Dunster Surgery (dispensing) GP Partner, Porlock Medical Centre Member of Somerset Primary Healthcare
Steve DuBois	Somerset Partnership Representative	Employee of Somerset Partnership NHS Foundation Trust. Pharmacy Management network team member. Lister House Surgery management has been taken over by Somerset Partnership. 3/17 - Took part in a group to develop a pharmacy education programme on Diabetes, it had no promotional content but was funded by the Novo Nordisk.
Dr Adrian Fulford	Taunton Representative	GP Partner , St James Medical Centre, Taunton Member of Somerset Primary Healthcare
Shaun Green	Head of Medicines Management	No conflicts 2016-17
Liz Harewood	Somerset Partnership Representative	Occasional attendance at pharmaceutical industry supported meetings & training. Will advise if related to any medicine under discussion.
Catherine Henley	Medicines Manager, NHS Somerset CCG	Practice Pharmacist at Wellington Medical Centre and Work as a locum pharmacist in Community Pharmacy. Ad hoc Consultancy work 17/12/15 NHIS Virtual Advisory Board on the treatment of depression. -Sponsored by Lundbeck
Dr Piers Jennings	East/West/Central Mendip Federation Representative	GP Partner and Prescribing and Dispensing Lead, Mendip Country Practice, Coleford. Member of Somerset Primary Healthcare
Dr Catherine Lewis	Bridgwater Representative	GP Partner Victoria Park Medical Centre Member of Bridgwater Bay Federation Executive Committee. Member of Somerset Primary Healthcare
Michael Lennox	LPC Representative	Chief Officer Somerset LPC Head of Operations Clinical Pharmacy Services Livewell Southwest (CIC NHS community and

Name	Position	Interests Declared
		<p>mental health provider across South Devon)</p> <p>Director of Lennox Health Partnerships (ad hoc consultancy)</p> <p>Pending joining of council of National association of Primary care as a representative for community pharmacy</p>
Sam Morris	Medicines Manager, NHS Somerset CCG	Zero hour contract pharmacist for Boots.
Dr Robert Munro	LMC Representative	<p>GP North Petherton, Provides Out-of-Hours services for Somerset Doctors and Urgent Care (SDUC)</p> <p>Member of Somerset Primary Healthcare</p>
Dr James Nicholls	West Mendip Representative	<p>GP Partner Vine Surgery (Wolfe)</p> <p>Member of Somerset Primary Healthcare</p>
Dr Carol Reynolds	North Sedgemoor Representative	<p>GP Partner Brent Area Medical Centre (Dispensing practice)</p> <p>Member of Somerset Primary Healthcare</p>